GLP-1 works by signaling the brain that the body is full, even with smaller portions of food, and by slowing the emptying of the stomach
Dehydration is a potential complication that can occur in people using GLP-1 receptor agonist injections, such as semaglutide (Wegovy) and tirzepatide (Mounjaro), for weight management or diabetes control
Following the release of a drug, the FAERS database collects adverse events reports from providers and patients that are witnessed in-market (i.e., in the real world practice of medicine rather than during a clinical trial or drug testing process)
Were here to support your weight and wellness journey every step of the way
The robustness of our results was further supported by high adherence levels in both drug classes, as evidenced by MPR
For individuals with obesity or those at risk of developing type 2 diabetes, GLP-1 injections offer a proven option to help manage weight and improve overall health